Bristol Myers Squibb Reports First Quarter Financial Results for 2021
Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY; Revenue Increase of 8% Excluding COVID-19 Related Buying Patterns from Prior Year Period
Posts First Quarter Earnings Per Share of $0.89 and Non-GAAP EPS of $1.74
Strengthens Leadership in Immuno-Oncology with Multiple Regulatory and Data Milestones for Opdivo and Yervoy
Delivers Positive Results from Phase 2/3 RELATIVITY-047 Trial Evaluating Relatlimab and Opdivo for Previously Untreated Metastatic or Unresectable Melanoma
Advances Cell Therapy Franchise with FDA Approvals for Abecma and Breyanzi
Presents Positive Results from POETYK-1 and POETYK-PSO-2 Phase 3 Trial Evaluating Deucravacitinib (TYK2 inhibito
